- Home
- OMC vs RPRX Comparison
OMC vs RPRX Comparison
Compare OMC & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMC
- RPRX
- Stock Information
- Founded
- OMC 1944
- RPRX 1996
- Country
- OMC United States
- RPRX United States
- Employees
- OMC N/A
- RPRX N/A
- Industry
- OMC Advertising
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- OMC Consumer Discretionary
- RPRX Health Care
- Exchange
- OMC Nasdaq
- RPRX Nasdaq
- Market Cap
- OMC 14.9B
- RPRX 16.2B
- IPO Year
- OMC N/A
- RPRX 2020
- Fundamental
- Price
- OMC $72.33
- RPRX $39.23
- Analyst Decision
- OMC Buy
- RPRX Strong Buy
- Analyst Count
- OMC 7
- RPRX 3
- Target Price
- OMC $96.57
- RPRX $46.00
- AVG Volume (30 Days)
- OMC 3.3M
- RPRX 3.8M
- Earning Date
- OMC 10-21-2025
- RPRX 11-05-2025
- Dividend Yield
- OMC 3.88%
- RPRX 2.21%
- EPS Growth
- OMC N/A
- RPRX N/A
- EPS
- OMC 6.79
- RPRX 1.75
- Revenue
- OMC $16,065,300,000.00
- RPRX $2,349,844,000.00
- Revenue This Year
- OMC $4.63
- RPRX $36.16
- Revenue Next Year
- OMC $3.28
- RPRX $2.04
- P/E Ratio
- OMC $10.64
- RPRX $22.68
- Revenue Growth
- OMC 4.13
- RPRX 3.70
- 52 Week Low
- OMC $68.37
- RPRX $24.05
- 52 Week High
- OMC $105.99
- RPRX $41.24
- Technical
- Relative Strength Index (RSI)
- OMC 37.85
- RPRX 59.26
- Support Level
- OMC $71.11
- RPRX $38.39
- Resistance Level
- OMC $74.57
- RPRX $40.01
- Average True Range (ATR)
- OMC 1.77
- RPRX 1.26
- MACD
- OMC -0.25
- RPRX 0.12
- Stochastic Oscillator
- OMC 15.98
- RPRX 63.19
About OMC Omnicom Group Inc.
Omnicom is a holding company that owns several advertising agencies and related firms. It provides traditional and digital advertising services that include creative design, market research, data analytics, ad placement, and public relations. The firm operates globally, providing services in more than 70 countries; it generates more than one half of its revenue in North America and nearly 30% in Europe.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.